Duplication of Glu37 in the switch I region of HRAS impairs effector/GAP binding and underlies Costello syndrome by promoting enhanced growth factor-dependent MAPK and AKT activation
Open Access
- 8 December 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 19 (5) , 790-802
Abstract
Costello syndrome (CS) is a developmental disorder characterized by postnatal reduced growth, facial dysmorphism, cardiac defects, mental retardation and skin and musculo-skeletal defects. CS is caused by HRAS germline mutations. In the majority of cases, mutations affect Gly12 and Gly13 and are associated with a relatively homogeneous phenotype. The same amino acid substitutions are well known as somatic mutations in human tumors and promote constitutive HRAS activation by impairing its GTPase activity. In a small number of cases with mild phenotype, a second class of substitutions involving codons 117 and 146 and affecting GTP/GDP binding has been described. Here, we report on the identification and functional characterization of two different three-nucleotide duplications resulting in a duplication of glutamate 37 (p.E37dup) associated with a homogeneous phenotype reminiscent of CS. Ectopic expression of HRASE37dup in COS-7 cells resulted in enhanced growth factor-dependent stimulation of the MEK-ERK and phosphoinositide 3-kinase (PI3K)-AKT signaling pathways. Recombinant HRASE37dup was characterized by slightly increased GTP/GDP dissociation, lower intrinsic GTPase activity and complete resistance to neurofibromin 1 GTPase-activating protein (GAP) stimulation due to dramatically reduced binding. Co-precipitation of GTP-bound HRASE37dup by various effector proteins, however, was inefficient because of drastically diminished binding affinities. Thus, although HRASE37dup is predominantly present in the active, GTP-bound state, it promotes only a weak hyperactivation of downstream signaling pathways. These findings provide evidence that the mildly enhanced signal flux through the MAPK and PI3K-AKT cascades promoted by these disease-causing germline HRAS alleles results from a balancing effect between a profound GAP insensitivity and inefficient binding to effector proteins.Keywords
This publication has 58 references indexed in Scilit:
- Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hairNature Genetics, 2009
- Novel type of Ras effector interaction established between tumour suppressor NORE1A and Ras switch IIThe EMBO Journal, 2008
- Ras oncogenes and their downstream targetsBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2007
- Mutations of the Mitochondrial Holocytochrome c–Type Synthase in X-Linked Dominant Microphthalmia with Linear Skin Defects SyndromeThe American Journal of Human Genetics, 2006
- GTPase activating proteins: structural and functional insights 18 years after discoveryCellular and Molecular Life Sciences, 2005
- Germline mutations in HRAS proto-oncogene cause Costello syndromeNature Genetics, 2005
- The RAF proteins take centre stageNature Reviews Molecular Cell Biology, 2004
- The Guanine Nucleotide-Binding Switch in Three DimensionsScience, 2001
- The Ras-RasGAP Complex: Structural Basis for GTPase Activation and Its Loss in Oncogenic Ras MutantsScience, 1997
- Phosphatidylinositol-3-OH kinase direct target of RasNature, 1994